Cypherpunk Technologies posted a Q3 2025 net loss of $3.3 million, substantially narrower than the $18.2 million loss in Q3 2024, reflecting a major reduction in research and development expenses following a corporate restructuring and trial completions.
Net loss narrowed to $3.3 million from $18.2 million in Q3 2024.
R&D expenses dropped to $1.2 million, down from $14.9 million.
G&A expenses declined to $1.9 million from $2.9 million.
Cash balance stood at $9.7 million at quarter end, before a $58.88M private placement in October.
Cypherpunk will focus on advancing ZEC acquisition and the development of its oncology pipeline, including next steps for sirexatamab regulatory submissions in 2026.
Analyze how earnings announcements historically affect stock price performance